<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36373411</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>Humoral and cellular immunogenicity and efficacy of a coxsackievirus A10 vaccine in mice.</ArticleTitle><Pagination><StartPage>e2147022</StartPage><MedlinePgn>e2147022</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2147022</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2022.2147022</ELocationID><Abstract><AbstractText>Coxsackievirus A10 (CV-A10) has become one of the major pathogens of hand, foot and mouth disease (HFMD), and studies on the vaccine and animal model of CV-A10 are still far from complete. Our study used a mouse-adapted CV-A10 strain, which was lethal for 14-day-old mice, to develop an infected mouse model. Then this model was employed to establish an actively immunized-challenged mouse model to evaluate the efficacy of a formaldehyde-inactivated CV-A10 vaccine, which was prepared from a Vero cell-adapted strain. CV-A10 vaccine at a dose of 0.5 or 2.0&#x2005;&#x3bc;g was inoculated intraperitoneally in neonatal Kunming mice on the third and ninth day. Then the mice were challenged on day 14. The survival rate of mice immunized with 0.5 or 2.0&#x2005;&#x3bc;g vaccine were 90% and 100%, respectively, while all Alum-inoculated mice died. Compared to those in the two vaccinated groups, the Alum-inoculated mice showed severe pathological damage, strong viral protein expression and high viral loads. The antisera from vaccinated mice showed high level of neutralizing antibodies against CV-A10. Meanwhile, three potential T cell epitopes located at the carboxyl-terminal regions of the VP1 and VP3 were identified and exhibited CV-A10 serotype-specific. The humoral and cellular immunogenicity analysis showed that immunization with two doses of the vaccine elicited CV-A10 specific neutralizing antibody and T cell response in BALB/c mice. Collectively, these findings indicated that this actively immunized-challenged mouse model will be invaluable in future studies on CV-A10 pathogenesis and evaluation of vaccine candidates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>An</LastName><ForeName>Huan-Huan</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>College of Medical Laboratory Science, Guilin Medical University, Guilin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Rui-Lun</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Sheng-Li</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ze-Jun</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Sha-Sha</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>34S289N54E</RegistryNumber><NameOfSubstance UI="C041524">aluminum sulfate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>16VY3TM7ZO</RegistryNumber><NameOfSubstance UI="C052091">antineoplaston A10</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000715067">Kunming mice</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CV-A10 vaccine</Keyword><Keyword MajorTopicYN="N">T cell epitope</Keyword><Keyword MajorTopicYN="N">active immunization-challenge</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">humoral and cellular immunogenicity</Keyword><Keyword MajorTopicYN="N">mouse model</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>14</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36373411</ArticleId><ArticleId IdType="pmc">PMC9848378</ArticleId><ArticleId IdType="doi">10.1080/22221751.2022.2147022</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fang CY, Liu CC.. Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies. Expert Opin Drug Discov. 2022;17(1):27&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">34382876</ArticleId></ArticleIdList></Reference><Reference><Citation>Min N, Ong YHB, Han AX, et al. . An epidemiological surveillance of hand foot and mouth disease in paediatric patients and in community: a Singapore retrospective cohort study, 2013-2018. PLoS Negl Trop Dis. 2021;15(2):e0008885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901731</ArticleId><ArticleId IdType="pubmed">33566802</ArticleId></ArticleIdList></Reference><Reference><Citation>He XC, Zhang MM, Zhao C, et al. . From monovalent to multivalent vaccines, the exploration for potential preventive strategies against hand, foot, and mouth disease (HFMD). Virol Sin. 2021;36(2):167&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7525078</ArticleId><ArticleId IdType="pubmed">32997323</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomqvist S, Klemola P, Kaijalainen S, et al. . Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virol. 2010;48(1):49&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189452</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yeo A, Phoon MC, et al. . The largest outbreak of hand foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis. 2010;14(12):e1076&#x2013;e1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MY, He SZ, Yan Q, et al. . Severe hand, foot and mouth disease associated with coxsackievirus A10 infections in Xiamen, China in 2015. J Clin Virol. 2017;93:20&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">28577423</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng XD, Tong YQ, Wei ZN, et al. . Epidemical and etiological study on hand, foot and mouth disease following EV-A71 vaccination in Xiangyang, China. Sci Rep. 2020;10(1):20909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7708472</ArticleId><ArticleId IdType="pubmed">33262488</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Yang XH, Hu SQ, et al. . Co-circulation of coxsackieviruses A-6, A-10, and A-16 causes hand, foot, and mouth disease in Guangzhou city, China. BMC Infect Dis. 2020;20(1):271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7137261</ArticleId><ArticleId IdType="pubmed">32264839</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuschino ME, Lamson DM, Rush K, et al. . Detection of coxsackievirus A10 in multiple tissues of a fatal infant sepsis case. J Clin Virol. 2012;53(3):259&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">22209288</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu QB, Zhang XA, Wo Y, et al. . Circulation of coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009-2011. PLoS One. 2012;7(12):e52073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3525556</ArticleId><ArticleId IdType="pubmed">23272213</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou JY, Shi YY, Miao L, et al. . Molecular epidemiology and recombination of enterovirus A71 in mainland China from 1987 to 2017. Int Microbiol. 2021;24(3):291&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7895512</ArticleId><ArticleId IdType="pubmed">33608776</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi EJ, Shin YJ, Kim JH, et al. . Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res. 2017;6(1):4&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZJ, Dong ZP, Li J, et al. . Protective efficacies of formaldehyde-inactivated whole-virus vaccine and antivirals in a murine model of coxsackievirus A10 infection. J Virol. 2017;91(13):e00333&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5469256</ArticleId><ArticleId IdType="pubmed">28424287</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SX, Zhao H, Yang LS, et al. . A neonatal mouse model of coxsackievirus A10 infection for anti-viral evaluation. Antiviral Res. 2017;144:247&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">28625478</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Xia Y, Zhu SR, et al. . Muscle destruction caused by coxsackievirus A10 in gerbils: construction of a novel animal model for antiviral evaluation. Virus Res. 2020;286:198067.</Citation><ArticleIdList><ArticleId IdType="pubmed">32553610</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao WJ, Yue L, Yang T, et al. . Proliferation characteristics of coxsackievirus A10 in mice and immune protection ability of experimental inactivated vaccine. Biomed Pharmacother. 2021;143:112212.</Citation><ArticleIdList><ArticleId IdType="pubmed">34649345</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen CY, Liu QW, Zhou Y, et al. . Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. Vaccine. 2016;34(41):5005&#x2013;5012.</Citation><ArticleIdList><ArticleId IdType="pubmed">27562093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Zhang C, Liu QW, et al. . A virus-like particle vaccine protects mice against coxsackievirus A10 lethal infection. Antiviral Res. 2018;152:124&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">29470994</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai WL, Zhang C, et al. . A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7(1):94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, Yu S, Guo YZ, et al. . Development of a multivalent enterovirus subunit vaccine based on immunoinformatic design principles for the prevention of HFMD. Vaccine. 2020;38(20):3671&#x2013;3681.</Citation><ArticleIdList><ArticleId IdType="pubmed">32247566</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZJ, Dong ZP, Wang Q, et al. . Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine. 2018;36(46):7095&#x2013;7104.</Citation><ArticleIdList><ArticleId IdType="pubmed">30316529</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan SQ, Yang FM, Li YY, et al. . Pathogenic analysis of coxsackievirus A10 in rhesus macaques. Virol Sin. 2022;37(4):610&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9437613</ArticleId><ArticleId IdType="pubmed">35777657</ArticleId></ArticleIdList></Reference><Reference><Citation>Standardization Administration of China . Laboratory animal guideline for ethical review of animal welfare. Beijing: Standardization Administration of China; 2018.</Citation></Reference><Reference><Citation>Qian SS, Wei ZN, Jin WP, et al. . Efficacy of a coxsackievirus A6 vaccine candidate in an actively immunized mouse model. Emerg Microbes Infect. 2021;10(1):763&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8079124</ArticleId><ArticleId IdType="pubmed">33739899</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H.. A simple method of estimating 50 percent end-points. Am J Epidemiol. 1938;27(3):493&#x2013;497.</Citation></Reference><Reference><Citation>Jin WP, Lu J, Zhang XY, et al. . Efficacy of coxsackievirus A5 vaccine candidates in an actively immunized mouse model. J Virol. 2021;95:e01743&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094937</ArticleId><ArticleId IdType="pubmed">33408178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu G, Jin WP, Yang ZH, et al. . Efficacy of coxsackievirus A2 vaccine candidates correlating to humoral immunity in mice challenged with a mouse-adapted strain. Vaccine. 2022;40(33):4716&#x2013;4725.</Citation><ArticleIdList><ArticleId IdType="pubmed">35760737</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo HM, et al. . A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol. 2012;86(4):2121&#x2013;2131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips BA, Fennell R.. Polypeptide composition of poliovirions, naturally occurring empty capsids, and 14S precursor particles. J Virol. 1973;12(2):291&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC356623</ArticleId><ArticleId IdType="pubmed">4355933</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZJ, Dong ZP, Wei QJ, et al. . A neonatal murine model of coxsackievirus A6 infection for evaluation of antiviral and vaccine efficacy. J Virol. 2017;91(9):e02450&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391469</ArticleId><ArticleId IdType="pubmed">28250116</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZJ, Zhang XC, Carr MJ, et al. . A neonatal murine model of coxsackievirus A4 infection for evaluation of vaccines and antiviral drugs. Emerg Microbes Infect. 2019;8(1):1445&#x2013;1455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792045</ArticleId><ArticleId IdType="pubmed">31595827</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang KT, Lin SJ, Wang HC, et al. . Establishment of an animal challenge model as a potency assay for an inactivated enterovirus type 71 vaccine. Biologicals. 2016;44(4):183&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">27068365</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Devi S, Cardosa MJ, et al. . Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol. 2010;84(1):661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Wang YP, Gao R, et al. . A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol. 2012;86(22):11967&#x2013;11976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3486452</ArticleId><ArticleId IdType="pubmed">22951825</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin ZC, Wu YY, Zhu R, et al. . Development of a neonatal mouse model for coxsackievirus B1 antiviral evaluation. Virol Sin. 2021;36(6):1575&#x2013;1584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8476979</ArticleId><ArticleId IdType="pubmed">34581960</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Huang YH, Tsai HP, et al. . A selective bottleneck shapes the evolutionary mutant spectra of enterovirus A71 during viral dissemination in humans. J Virol. 2017;91(23):e01062&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5686718</ArticleId><ArticleId IdType="pubmed">28931688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji WQ, Qin LW, Tao L, et al. . Neonatal murine model of coxsackievirus A2 infection for the evaluation of antiviral therapeutics and vaccination. Front Microbiol. 2021;12:658093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8192712</ArticleId><ArticleId IdType="pubmed">34122374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren R, Racaniello VR.. Poliovirus spreads from muscle to the central nervous system by neutral pathways. J Infect Dis. 1992;166(4):747&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">1326581</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin PF, Li JX, Zhang XF, et al. . Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months. Hum Vaccin Immunother. 2016;12(4):916&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962943</ArticleId><ArticleId IdType="pubmed">26751765</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu R, Cheng T, Yin ZC, et al. . Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population. Emerg Microbes Infect. 2018;7(1):2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837151</ArticleId><ArticleId IdType="pubmed">29323107</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck MA, Tracy SM.. Murine cell-mediated immune response recognizes an enterovirus group-specific antigen(s). J Virol. 1989;63(10):4148&#x2013;4156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC251028</ArticleId><ArticleId IdType="pubmed">2476566</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutubuddin M, Simons J, Chow M.. Identification of T-helper epitopes in the VP1 capsid protein of poliovirus. J Virol. 1992;66(5):3042&#x2013;3047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC241064</ArticleId><ArticleId IdType="pubmed">1373200</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahon BP, Katrak K, Mills KH.. Antigenic sequences of poliovirus recognized by T cells: serotype-specific epitopes on VP1 and VP3 and cross-reactive epitopes on VP4 defined by using CD4+ T-cell clones. J Virol. 1992;66(12):7012&#x2013;7020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240354</ArticleId><ArticleId IdType="pubmed">1279196</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DGW, Macary PA, Alonso S, et al. . Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71. Viral Immunol. 2008;21(2):215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">18419256</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei RC, Yang CF, Zeng M, et al. . A dominant EV71-specific CD4+ T cell epitope is highly conserved among human enteroviruses. PLoS One. 2012;7(12):e51957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522610</ArticleId><ArticleId IdType="pubmed">23251663</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan SG, Tian XG, Sun XM, et al. . VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population. J Immunol. 2013;191(4):1637&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pubmed">23863902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Perosanz M, Sanchez-Trincado JL, Fernandez-Arquero M, et al. . Human rhinovirus-specific CD8 T cell responses target conserved and unusual epitopes. FASEB J. 2021;35(1):e21208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753581</ArticleId><ArticleId IdType="pubmed">33230881</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>